These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 9365601)

  • 1. Indications for mycofenolate mofetil therapy after liver transplantation.
    Platz KP; Mueller AR; Neuhaus P
    Transplant Proc; 1997 Nov; 29(7):2880-1. PubMed ID: 9365601
    [No Abstract]   [Full Text] [Related]  

  • 2. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation.
    Platz KP; Mueller AR; Willimski C; Mansoorian B; Berg T; Neuhaus R; Hopf U; Lobeck H; Neuhaus P
    Transplant Proc; 1998 Jun; 30(4):1468-9. PubMed ID: 9636596
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversal of chronic rejection after treatment failure with FK506 and RS61443.
    Roberts JP; Lake JR; Hebert M; Nikolai B; Ascher NL; Ferrell LD
    Transplantation; 1993 Oct; 56(4):1021-3. PubMed ID: 7692634
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients.
    Tsang WK; Tong KL; Yeung S; Lee W; Chan HW
    Transplant Proc; 2000 Nov; 32(7):1755-6. PubMed ID: 11119921
    [No Abstract]   [Full Text] [Related]  

  • 5. FK 506 and mycofenolate mofetil rescue for acute steroid-resistant and chronic rejection after liver transplantation.
    Platz KP; Mueller AR; Neuhaus R; Keck HH; Lobeck H; Neuhaus P
    Transplant Proc; 1997 Nov; 29(7):2872-4. PubMed ID: 9365598
    [No Abstract]   [Full Text] [Related]  

  • 6. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation.
    Klupp J; Glanemann M; Bechstein WO; Platz KP; Langrehr JM; Keck H; Settmacher U; Radtke C; Neuhaus R; Neuhaus P
    Transplant Proc; 1999; 31(1-2):1113-4. PubMed ID: 10083497
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of immunosuppressive drugs in transplantation.
    Triemer H
    J Med Assoc Ga; 1998 Apr; 87(2):93-6. PubMed ID: 16259250
    [No Abstract]   [Full Text] [Related]  

  • 8. Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function.
    Fritsche L; Sperschneider H; Budde K; Giessing M; Türk H; Böhler T; Schröder K; Stein G; Neumayer HH
    Transplant Proc; 1998 Aug; 30(5):2229. PubMed ID: 9723451
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipients.
    Suhail SM; Vathsala A; Lou HX; Woo KT
    Transplant Proc; 2000 Nov; 32(7):1757-8. PubMed ID: 11119922
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of the safety and efficacy of mycophenolate mofetil, prednisolone and cyclosporine and conventional cyclosporine and prednisolone in kidney transplantation.
    Kim HC; Park SB; Kim HT; Cho WH; Park CH
    Transplant Proc; 2000 Nov; 32(7):1751-2. PubMed ID: 11119919
    [No Abstract]   [Full Text] [Related]  

  • 11. Mycophenolate mofetil for treatment of ongoing or chronic rejections after liver transplantation.
    Pfitzmann R; Klupp J; Langrehr JM; Neuhaus R; Junge G; Settmacher U; Steinmüller T; Neuhaus P
    Transplant Proc; 2002 Nov; 34(7):2938-9. PubMed ID: 12431665
    [No Abstract]   [Full Text] [Related]  

  • 12. One hundred children treated with tacrolimus after primary orthotopic liver transplantation.
    McDiarmid S; Goss J; Seu P; Shackleton C; Vargas J; Ament M; Busuttil R
    Transplant Proc; 1998 Jun; 30(4):1397-8. PubMed ID: 9636564
    [No Abstract]   [Full Text] [Related]  

  • 13. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization.
    Smith JM; Nemeth TL; McDonald RA
    Pediatr Transplant; 2004 Oct; 8(5):445-53. PubMed ID: 15367279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction.
    Burke GW; Ciancio G; Alejandro R; Roth D; Ricordi C; Tzakis A; Miller J
    Transplant Proc; 1998 Jun; 30(4):1544-5. PubMed ID: 9636627
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycofenolate mofetil-cyclosporine immunosuppression of kidney transplantation recipients with two different corticosteroid doses.
    Remport A; Sasvári I; Toronyi E; Borka P; Lázár N; Járay J; Perner F
    Transplant Proc; 2001 May; 33(3):2302-3. PubMed ID: 11377537
    [No Abstract]   [Full Text] [Related]  

  • 16. FK506 for primary and rescue therapy following liver transplantation.
    Platz KP; Mueller AR; Zytowski M; Lobeck H; Neuhaus P
    Transplant Proc; 1998 Jun; 30(4):1409-10. PubMed ID: 9636570
    [No Abstract]   [Full Text] [Related]  

  • 17. Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients.
    Park K; Kim SI; Moon JI; Kim YS; Kim MS
    Transplant Proc; 1998 Nov; 30(7):3575. PubMed ID: 9838565
    [No Abstract]   [Full Text] [Related]  

  • 18. Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection.
    Kato T; Ruiz P; DeFaria W; Weppler D; Khan F; Pinna A; Nery J; Tzakis A
    Transplant Proc; 1999; 31(1-2):396. PubMed ID: 10083158
    [No Abstract]   [Full Text] [Related]  

  • 19. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation.
    Eckhoff DE; McGuire BM; Frenette LR; Contreras JL; Hudson SL; Bynon JS
    Transplantation; 1998 Jan; 65(2):180-7. PubMed ID: 9458011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single centre experience with mycophenolate mofetil for refractory rejection in cadaveric renal transplantation.
    Morris-Stiff G; Jurewicz WA
    Transpl Int; 1998; 11(3):204-7. PubMed ID: 9638849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.